Rewriting the Rules of Biology: Dr. Chaska Walton and the Quest to Engineer Living Therapies for Alzheimer’s Disease

The landscape of modern biomedical research is increasingly defined by scientists who refuse to accept traditional boundaries, viewing biological systems not as immutable structures, but as programmable code. Among these pioneers is Dr. Chaska Walton, a researcher in Dr. Julie Andersen’s laboratory at the Buck Institute for Research on Aging. Walton recently earned one of the most selective and prestigious honors in American academic science: a $2.4 million NIH Transformative Research Award from the National Institutes of Health. With this funding, Walton is spearheading the development of smart delivery systems designed to tackle the multifaceted pathologies of Alzheimer’s disease.

The NIH Transformative Research Award is exceptionally rare. In the cycle recognizing Walton’s work, the agency distributed only nine such awards across the entire United States. The grant is designed to support cross-cutting, high-risk, high-reward scientific projects that have the potential to fundamentally alter entire fields of biomedical research. For Walton, this recognition serves as validation for an unconventional scientific philosophy that bridges neuroscience, synthetic biology, and translational medicine, operating under a guiding principle that views biological limits as temporary technological hurdles rather than permanent laws of nature.

A Global Scientific Trajectory

Walton’s journey to the forefront of synthetic neurobiology spans multiple countries, academic institutions, and disciplines. The scientific path began with undergraduate studies in psychology and neuroscience at the Autonomous University of Barcelona. Driven by a fundamental curiosity about the architecture and function of the brain, Walton transitioned to Madrid for doctoral studies, completing a PhD in molecular bioscience through a joint program with the Spanish National Research Council (CSIC) and the Autonomous University of Madrid, while conducting research at the renowned Cajal Institute.

During doctoral research in Madrid, Walton challenged long-standing neurobiological dogma. Conventional scientific consensus long held that mature neurons—having exited the cell cycle—could no longer divide or re-enter active cell proliferation. Walton’s work demonstrated that mature neurons could indeed re-enter the cell cycle, a discovery deeply aligned with the historical philosophy of Santiago Ramón y Cajal, who posited that the science of the future would eventually overturn even the most entrenched physiological rules.

Following the work in Spain, Walton brought this paradigm-shifting ethos to the Buck Institute in California. Initially focusing on the fundamental mechanisms of neuronal vulnerability and aging, the research focus subsequently evolved toward engineering living therapies. Today, Walton’s work centers on synthetic immune-cell therapies, including programmable chimeric antigen receptor regulatory T cells (CAR-Tregs) and smart cellular delivery platforms engineered to navigate the complex pathological landscape of neurodegenerative diseases.

The Analogy of the Broken Car: Rethinking Modern Medicine’s Approach to Alzheimer’s

To understand the urgency and uniqueness of Walton’s research, one must examine the philosophical critique he levies against contemporary medical intervention. In conventional drug development, complex diseases are frequently approached through a single-target lens. Walton illustrates this limitation with an automotive analogy.

Consider a car that experiences a flat tire. If the vehicle continues to drive on that flat tire, the wheel rim grinds against the asphalt, damaging the wheel assembly. The resulting stress strains the axle shaft, which eventually fractures, causing the car to scrape against the road, leak vital fluids, and ultimately destroy the engine. The approach of modern medicine, according to Walton, is to focus exclusively on fixing one component—repairing the flat tire, or replacing the wheel, or mending the axle, or rebuilding the engine—while expecting the entire multi-system machine to function properly based on that isolated repair.

In the context of Alzheimer’s disease, this single-target philosophy has dominated clinical trials for decades. Alzheimer’s is not a monolithic disorder driven by a single broken pathway; rather, it presents multiple, concurrent pathologies. These include the accumulation of toxic amyloid-beta and hyperphosphorylated tau aggregates, chronic neuroinflammation, hyper-reactive microglia, and progressive synapse dysfunction.

Despite the multiplicity of these pathological hallmarks, the vast majority of clinical trials evaluate therapeutic interventions that target only one of these features at a time. Zero clinical trials historically attempt to simultaneously resolve all primary pathological hallmarks of the disease. Yet, the medical establishment often expresses surprise when single-target therapies fail to reverse a multifaceted, systemic neurodegenerative cascade.

Living Therapeutics: Biological Nanobots in the Fight Against Neurodegeneration

Science fiction has long popularized the concept of microscopic nanobots patrolling the human body, acting as miniature physicians that detect cellular damage and administer targeted repairs. Walton’s lab is translating this speculative concept into biological reality, substituting mechanical machinery with living immune cells.

Rather than relying on synthetic hardware, Walton’s team is engineering immune cells to perform intelligent diagnostic and therapeutic functions. These engineered cells are designed to patrol the central nervous system, autonomously detect specific disease-associated molecular signatures characteristic of Alzheimer’s pathology, and respond by synthesizing and releasing therapeutic payloads directly at the site of damage. Crucially, these smart delivery platforms are programmed to self-regulate—delivering drugs with micrometer-scale precision and halting production when the pathological trigger is neutralized.

This cellular delivery system represents a paradigm shift from traditional pharmacokinetics, where drugs circulate systemically throughout the body, frequently causing off-target toxicity while failing to reach therapeutic concentrations within the brain due to the blood-brain barrier. By harnessing the natural homing capabilities of immune cells and superimposing synthetic regulatory circuits, Walton aims to create a cohesive therapeutic intervention capable of addressing multiple disease axes simultaneously.

The Philosophy of Editable Biology

Underpinning these technological innovations is Walton’s uncompromising view of human biology as programmable code. Addressing what first drew him to the field and what sustains his motivation, Walton emphasizes that biological limitations are transient reflections of current technological capacity rather than immutable physical laws.

"We are, in essence, editable code," Walton notes. "Some argue that we cannot edit ourselves, but that misses the point. It is not about whether we can do something today. In the Stone Age, humans could not fly, yet flight was never forbidden by physics. The limitation was technological, not fundamental. Likewise, biology does not forbid rewriting ourselves."

This perspective fuels an ambitious long-term outlook. Walton envisions a future where bioengineers routinely design custom proteins that natural evolution would never produce, expressing them within human cells to generate novel cell types, specialized functions, and duplicated or regenerated organs. By rejecting the premise that neurodegeneration is an inevitable consequence of aging, Walton positions aging and its associated pathologies as biological processes that can be systematically interrogated, engineered, and ultimately rewritten.

Broader Impact and Implications for the Future of Healthcare

The implications of Walton’s $2.4 million NIH-funded project extend far beyond the immediate confines of Alzheimer’s disease research. If successful, the development of programmable, multi-payload cellular delivery systems could redefine the treatment paradigms for a wide array of complex, multifactorial disorders that have long resisted pharmacological intervention, including Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and various forms of metabolic and autoimmune dysfunction.

As the scientific community grapples with the limitations of reductionist drug discovery, interdisciplinary approaches that combine synthetic biology, immunology, and neuroscience are gaining momentum. The work conducted at the Buck Institute under researchers like Walton and Andersen exemplifies a broader generational shift in biogerontology—moving from descriptive observation of aging processes to active, engineering-based interventions.

By challenging the dogmas of cell cycle regulation, rethinking the systemic architecture of neurodegeneration, and leveraging the programmable nature of living cells, Walton is helping to chart a new course for modern medicine. Diseases once deemed intractable are increasingly viewed through the lens of engineering challenges, bringing closer the day when complex pathologies can be intercepted, managed, and reversed through the power of smart biological design.